Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMal AF-HF
NCT07238452Phase 3Not yet recruiting
- Sponsor
- University of British Columbia
- Start
- Nov 2026
- Primary completion
- Dec 2032
01
Overview
Phase 3, randomised trial in Atrial fibrillation (AFib) and heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by University of British Columbia. Primary endpoint: Composite of time to first cardiovascular mortality, stroke, or heart failure event at 5 years. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
Atrial fibrillation (AFib)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07238452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07238452.